Literature DB >> 30717062

Wound healing complications after revascularization for moyamoya vasculopathy with reference to different skin incisions.

Güliz Acker1,2, Nicolas Schlinkmann1, Lucius Fekonja1,3, Lukas Grünwald1, Juliane Hardt4,5, Marcus Czabanka1, Peter Vajkoczy1.   

Abstract

OBJECTIVEMoyamoya vasculopathy (MMV) is a steno-occlusive cerebrovascular disease that can be treated by a surgical revascularization. All the revascularization techniques influence the blood supply of the scalp, with a risk for wound healing disorders. The authors' aim was to analyze the wound healing process in the patients who underwent a direct or combined bypass surgery with a focus on different skin incisions.METHODSThe authors retrospectively identified all the patients with MMV who were treated surgically in their institution. Subsequently, they analyzed demographic data, clinical symptoms, surgical treatment, and detailed history of complications. Based on the evolution of their surgical techniques and the revascularization strategy to be used, the authors applied the following skin incisions: linear incision, curved incision, incomplete Y incision, and complete Y incision. Group comparisons regarding wound healing disorders were performed with significance testing using Fisher's exact test.RESULTSThe authors identified 172 patients with MMV (61.6% moyamoya disease, 7% unilateral moyamoya disease, 29.7% moyamoya syndrome, and 1.7% unilateral moyamoya syndrome), of whom 124 underwent bilateral operations. One-quarter of the patients were juveniles. A total of 236 hemispheres were included in the analysis, of which 27.9% were treated by a combined procedure with encephalomyosynangiosis. Overall, 5.1% major and 1.7% minor wound complications occurred. The overall wound complication rate was lower in direct revascularization compared to combined revascularization (3% vs 15.2%). The lowest incidence of wound healing disorders was found in the linear incision group for the parietal superficial temporal artery branch (1.6%), followed by the incomplete Y incision group for the frontal branch of the superficial temporal artery (3.8%) in the direct bypass group. In the combined revascularization cohort, major or minor wound disorders appeared in 14.3% and 4.8%, respectively, in the complete Y incision group and in 4.2% (for both major and minor) in the curved incision group. The complete Y incision caused significantly more wound healing disorders compared to the remaining incision types (17.1% vs 3.1%, p = 0.007).CONCLUSIONSWound healing disorders are one of the major complications of revascularization surgery. Their incidence depends on the revascularization strategy and skin incision applied, with a complete Y incision giving the worst results.

Entities:  

Keywords:  EDAMS = encephaloduroarteriomyosynangiosis; EDAS = encephaloduroarteriosynangiosis; EMS; EMS = encephalomyosynangiosis; MCA = middle cerebral artery; MMD = moyamoya disease; MMS = moyamoya syndrome; MMV = moyamoya vasculopathy; STA = superficial temporal artery; STA-MCA; encephalomyosynangiosis; moyamoya disease; revascularization; superficial temporal artery–middle cerebral artery

Mesh:

Year:  2019        PMID: 30717062     DOI: 10.3171/2018.11.FOCUS18512

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  3 in total

1.  A Perioperative Paradigm of Cranioplasty With Polyetheretherketone: Comprehensive Management for Preventing Postoperative Complications.

Authors:  Zhenghui He; Yuxiao Ma; Chun Yang; Jiyuan Hui; Qing Mao; Guoyi Gao; Jiyao Jiang; Junfeng Feng
Journal:  Front Surg       Date:  2022-03-21

Review 2.  Current Surgical Options for Moyamoya Disease.

Authors:  Julie Mayeku; Miguel A Lopez-Gonzalez
Journal:  Cureus       Date:  2020-11-04

Review 3.  Limits and pitfalls of indirect revascularization in moyamoya disease and syndrome.

Authors:  Pietro Fiaschi; Marcello Scala; Gianluca Piatelli; Domenico Tortora; Francesca Secci; Armando Cama; Marco Pavanello
Journal:  Neurosurg Rev       Date:  2020-09-21       Impact factor: 3.042

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.